LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

0.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	605K -15M
Продажби	19M 40M
Марж на печалбата	-37.72
Служители	105
EBITDA	-3.6M -12M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+1058.33% upside

Дивиденти
By Dow Jones
Следващи печалби	12.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.1M 85M
Предишно отваряне	0.32
Предишно затваряне	0.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.08.2025 г., 23:09 ч. UTC

Придобивния, сливания и поглъщания

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22.08.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22.08.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22.08.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22.08.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22.08.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22.08.2025 г., 21:23 ч. UTC

Пазарно говорене

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22.08.2025 г., 21:18 ч. UTC

Пазарно говорене

US Economic Growth Seen Slowing This Year -- Market Talk

22.08.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

U.S. Takes 10% Stake in Intel -- Barrons.com

22.08.2025 г., 21:03 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.08.2025 г., 21:03 ч. UTC

Пазарно говорене

Mexican Stocks Close At Record High -- Market Talk

22.08.2025 г., 20:58 ч. UTC

Пазарно говорене

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22.08.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22.08.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22.08.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22.08.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22.08.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22.08.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22.08.2025 г., 20:56 ч. UTC

Печалби

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22.08.2025 г., 20:55 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

22.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

22.08.2025 г., 20:41 ч. UTC

Придобивния, сливания и поглъщания

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22.08.2025 г., 20:24 ч. UTC

Придобивния, сливания и поглъщания

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22.08.2025 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22.08.2025 г., 19:19 ч. UTC

Пазарно говорене

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22.08.2025 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22.08.2025 г., 19:06 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22.08.2025 г., 19:03 ч. UTC

Пазарно говорене

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22.08.2025 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Ценова цел

By TipRanks

1058.33% нагоре

12-месечна прогноза

Среден 4.17 USD 1058.33%

Висок 8 USD

Нисък 0.5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Vaxart Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.